A key message MacroGenics had for Margenza was that the HER2 drug topped Roche’s Herceptin in breast cancer patients. But now, that advantage is no more. A combination of Margenza and chemotherapy ...

Merck & Co.’s Keytruda has hit its marks in many tumor types but doesn’t exactly have a successful clinical history in stomach cancer. Now, the drug can at least tout an early win for a subgroup of ...

The most common infusion-related reactions when receiving Perjeta, Herceptin and docetaxel were feeling tired, abnormal or altered taste, allergic reactions, muscle pain and vomiting. The most common ...

Patients with HER2-positive metastatic breast cancer may receive sufficient first-line treatment with Perjeta plus Herceptin without chemotherapy. The treatment combination of Perjeta (pertuzumab) ...

Herceptin (trastuzumab) should be offered to patients with HER2-positive locally advanced or inflammatory breast cancer alongside chemotherapy. This is the conclusion of an Article in this week's ...

Oct 18 (Reuters) - Halozyme Therapeutics , which specializes in reformulating drug products available only as infusions, said a pivotal trial of subcutaneous Herceptin, the cancer drug sold by Roche , ...

— Follow-up data from pivotal Phase III APHINITY study evaluating Perjeta plus Herceptin and chemotherapy in HER2-positive early breast cancer — — Results from Phase III FeDeriCa study confirming the ...

SAN ANTONIO − The targeted therapy Herceptin helps women with HER2+ type of breast cancer independent of whether patients have extra copies of chromosome 17, home to the HER2 gene which produces the ...

Here's a Mayo Clinic study that came out Friday on a promising breast cancer treatment called Herceptin made by San Fran-based Genentech. SAN ANTONIO — The targeted therapy Herceptin helps women with ...